Once-daily dosing designed for flexibility Tablet and oral liquid options taken once a day help fit treatment into daily life. Understanding KYMBEE™ dosing KYMBEE (deflazacort), indicated for Duchenne muscular dystrophy (DMD) in patients 2 years of age and older, is available in two formulations to support different needs. Refer to the Important Safety Information and discuss any side effects or symptoms with your healthcare provider immediately. Tablet and liquid options For children who may have difficulty swallowing tablets, an oral liquid formulation is also available. Tablet formulation Available in 6 mg, 18 mg, 30 mg, and 36 mg strengths May be taken whole or crushed and taken immediately after mixing with applesauce Liquid formulation 22.75 mg/mL oral suspension Mix well with 3–4 oz of juice or milk and give immediately Taking KYMBEE General considerations for both tablet and liquid formulations: KYMBEE can be taken with or without food Do not take KYMBEE with grapefruit juice Do not stop treatment without consulting a healthcare provider Do not use KYMBEE if your child is allergic to deflazacort or any of its inactive ingredients Store at room temperature (68°F to 77°F) Considerations for liquid formulation: Make sure the bottle cap is put on tightly and shake well prior to measuring out each dose Only use the oral dispenser provided with the product to measure a dose Replace cap tightly and clean the oral dispenser after each use Discard any unused portion 1 month after opening For information on administration of the oral suspension, refer to the KYMBEE Instructions for Use Have questions about treatment? Find helpful information for conversations with your child’s healthcare provider about KYMBEE Getting started with KYMBEE Questions about starting or managing treatment? Find the information you need to take the next step with KYMBEE. Getting started with KYMBEE Savings and support Explore FAQs Request to stay informed IMPORTANT SAFETY INFORMATION & INDICATION for KYMBEE™ (deflazacort) Who should not take KYMBEE? Do not take if you have had hypersensitivity, including allergic reactions, to deflazacort (the active ingredient in KYMBEE) or to any of the inactive ingredients in KYMBEE. What is the most important information I should know about KYMBEE? KYMBEE can cause changes in endocrine (hormone) function. Do not stop taking KYMBEE, or change the amount being taken, without first checking with a healthcare provider, as there may be a need for gradual dose reduction to decrease the risk of adrenal insufficiency and steroid “withdrawal syndrome.” Acute adrenal insufficiency can occur if corticosteroids, including KYMBEE, are withdrawn abruptly, and can be life threatening. A steroid “withdrawal syndrome” may also occur following abrupt discontinuance of corticosteroids. For patients already taking corticosteroids during times of stress, the dosage may need to be increased. There is an increased risk of infection when taking KYMBEE. Tell a healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Seek medical advice immediately if the patient develops fever or other signs of infection. Some infections can potentially be severe and life threatening. Patients should avoid exposure to chickenpox or measles and alert their healthcare provider immediately if they are exposed. KYMBEE can cause an increase in blood pressure and water retention. If this occurs, dietary salt restriction and potassium therapy may be needed. There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like KYMBEE. KYMBEE can cause behavior and mood changes that can be severe. Seek medical attention if any behavioral or mood changes develop. There is a risk of osteoporosis with prolonged use of KYMBEE, which can lead to fractures in the spine and in long bones. KYMBEE may cause cataracts or glaucoma. A healthcare provider should monitor for these conditions if therapy is continued for more than 6 weeks. Immunizations should be up-to-date according to immunization guidelines prior to starting therapy with KYMBEE. Live attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting KYMBEE. Live attenuated or live vaccines should not be used in patients taking KYMBEE. KYMBEE can cause serious skin rashes. Seek medical attention at the first sign of a rash. Rare instances of anaphylaxis, a severe allergic reaction, have occurred in patients receiving corticosteroid therapy, including KYMBEE. KYMBEE Oral Suspension contains the preservative benzyl alcohol which can cause serious side effects in infants. It is not approved for use in patients less than 2 years of age. Before taking KYMBEE, tell a healthcare provider about all medical conditions, including if the patient: is pregnant or planning to become pregnant. KYMBEE can harm an unborn baby. is breastfeeding or planning to breastfeed. Deflazacort may appear in breastmilk and could affect a nursing child. Certain medications can cause an interaction with KYMBEE. Tell a healthcare provider about all the medicines you are taking, including over-the-counter medicines (such as insulin, aspirin or other non-steroidal anti-inflammatory drugs), dietary supplements, and herbal products. Alternate treatment, dosage adjustment, and/or special test(s) may be needed during the treatment. What are the side effects of KYMBEE? The most common side effects include: facial puffiness or Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, frequent daytime urination, unwanted hair growth, abdominal obesity, and colds. These are not all of the possible side effects. Call a healthcare provider for medical advice about side effects. What is KYMBEE? KYMBEE (deflazacort) is a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. KYMBEE is available in 6 mg, 18 mg, 30 mg, and 36 mg tablets. KYMBEE is also available as a 22.75 mg/mL oral suspension. This safety information is not comprehensive. Please see the full Prescribing Information for more information on KYMBEE and the Instructions for Use. You can also visit www.upsher-smith.com or call 1-888-650-3789. You are encouraged to report suspected adverse reactions to the FDA by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088.